18 November 2025
: Case report 
Exploring Maralixibat for Treatment-Resistant Pruritus in Intrahepatic Cholestasis of Pregnancy and Primary Biliary Cholangitis: A Case Report
Unusual clinical course, Challenging differential diagnosis, Unusual setting of medical care, Patient complains / malpractice, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
Lara Alexandra Bersuch
ABCDEF 1*, Andrea De Gottardi DE 1,2
DOI: 10.12659/AJCR.949019
Am J Case Rep 2025; 26:e949019
Figure 1 Clinical course of pruritus and bile acids during pregnancy and treatmentThe graph illustrates the progression of pruritus intensity, measured by the Visual Analog Scale (VAS), and serum bile acid (sBA) levels from initial presentation at the hepatology department through treatment with ursodeoxycholic acid (UDCA). Time points for therapeutic interventions are color-coded, indicating the initiation and dose adjustments of UDCA, cholestyramine, and maralixibat. The horizontal yellow line denotes the sBA threshold of 100 μmol/L, above which induction of labor is recommended. Labor was induced immediately after sBA levels exceeded this threshold, as indicated by the arrow.